Evidence map›Paper›PMID 20945381›Full record

ArticleJournal of cellular physiology2011

Oncoprotein Cot1 represses kinase suppressors of Ras1/2 and 1,25-dihydroxyvitamin D3-induced differentiation of human acute myeloid leukemia cells.

Xuening Wang, George P Studzinski

Abstract read
In one paragraph

Article in Journal of cellular physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis.International journal of molecular sciences · 2019
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Xuening WangDepartment of Pathology and Laboratory Medicine, UMDNJ-New Jersey Medical School, Newark, New Jersey 07101-1709, USA.
George P Studzinski
Rutgers New Jersey Medical School

Funding

Vitamin D Analogs as Adjuvants in Chemotherapy of CancerR01CA044722 · NCI · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI STUDZINSKI, GEORGE P · 1987 to 2016
$3.5M
VITAMIN D PLANT ANTIOXIDANT SILIBININ IN LEUKEMIA TRANSLATIONAL STUDYR01CA117942 · NCI · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI STUDZINSKI, GEORGE P · 2007 to 2010
$772k
NCI NIH HHS R01 CA044722NCI NIH HHS R01 CA117942NCI NIH HHS R01-CA-117942-03NCI NIH HHS R01-CA-44722-20
6 · The paper itself

Abstract

Metabolites and derivatives of vitamin D are well-known inducers of monocytic differentiation, but the mechanistic basis for their action is not fully elucidated. Here we show that the product of protooncogene Cot1 represses the monocytic phenotype in human acute myeloid leukemia (AML) cells induced to differentiate by 1,25-dihydroxyvitamin D(3) (1,25D), even though the expression of cellular Cot1 increases early in the process of 1,25D-induced differentiation. Interestingly, the expression of the two members of the Kinase Suppressor of Ras (KSR) family of molecular scaffolds, known to be positive regulators of Ras signaling and of 1,25D-induced differentiation, increases in parallel with Cot1 in 1,25D-treated cells. However, KSR1/2 are negatively regulated by Cot1, as determined by transfection of siCot1, and confirmed by a reverse effect of ectopic expression of Cot1. The effect of Cot1 in AML cells appears to be cell-type specific, as previous reports in other cell types found KSR-2 to be a negative regulator of Cot1, a reverse relationship. Also in contrast to findings in other cells, in AML cells Cot1 exerts negative control on the MAP kinase pathways, since siCot1 increases the levels of activated Raf1, p90RSK, JNK1, c-jun, and p38, though not of MEK/ERK. These findings have implications for therapy of AML, since in AML cells active MAPKs hasten cell differentiation, and specific pharmacological inhibitors of Cot1 kinase activity have recently became available, thus making Cot1 a "druggable" target.

Indexed as

Antineoplastic AgentsCalcitriolCell DifferentiationDown-RegulationExtracellular Signal-Regulated MAP KinasesHL-60 CellsHumansLeukemia, Myeloid, AcuteMAP Kinase Kinase KinasesMitogen-Activated Protein Kinase 8Monocytesp38 Mitogen-Activated Protein KinasesPhenotypeProtein KinasesProtein Serine-Threonine KinasesProto-Oncogene ProteinsAntineoplastic AgentsCalcitriolExtracellular Signal-Regulated MAP KinasesKSR-1 protein kinaseKSR2 protein, humanMAP3K8 protein, humanMAP Kinase Kinase KinasesMitogen-Activated Protein Kinase 8p38 Mitogen-Activated Protein KinasesProtein KinasesProtein Serine-Threonine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-junProto-Oncogene Proteins c-rafRibosomal Protein S6 Kinases, 90-kDa

Identifiers

PMID20945381
PMCPMC3440184
OpenAlexW2069297382

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.